To get BP under control, combination of
medicines may be best
Newswise — Single tablets
containing two drugs may be the key to
increasing blood pressure control rates from 36
percent to over 80 percent in the U.S.
Millions of Americans take medications for
hypertension but do not achieve control of their
blood pressure. Single-tablet combinations of
drugs may be what it takes to get blood pressure
under control, even in people with moderate
hypertension, according to results from a new
international study involving more than 10,700
people with high blood pressure.
Just six months of
treatment was enough to bring the blood pressure
of 73 percent of patients into an acceptable
range, with an average reading of 132/74 mmHg.
That’s a near-doubling of the proportion that
started the study with their hypertension under
control -- despite the fact that nearly all
patients came into the study on other medication
before switching to one of the two-drug
combinations used in the study.
A year later, after 18
months of treatment, patients continued to have
good blood pressure control. In fact, more than
80 percent of participants from the United
States achieved control, with a mean systolic
blood pressure of 129mmHg. This is exceptional
news in that only 36 percent of study subjects
in the U.S. treated by clinicians achieve a
blood pressure of 140/90.
The news was also good
among people with diabetes or kidney disease —
who need to aim for lower blood pressures than
others in order to reduce their risk of heart
disease and stroke, but who often have a harder
time getting their BP down. People with diabetes
in the study achieved a mean systolic BP of 131
mmHg while those with chronic kidney disease
were at 136 mmHg. These groups also saw
sustained blood pressure control.
There were few side effects
in the study volunteers, despite the fact that
doses were increased steadily. Only 1.8 percent
of patients had an episode where their blood
pressure dropped too low – a potential effect of
aggressive BP treatment.
“These data suggest
strongly that single tablets containing two
drugs will control the vast majority of patients
who are taking medication but have not achieved
ideal blood pressure. These data may affect the
blood pressure control of over 38 million
Americans,” says study leader and lead author
Ken Jamerson, M.D. a professor of cardiovascular
medicine at the University of Michigan Medical
School and member of the U-M Cardiovascular
Center.
Jamerson presented the
18-month data today at the American Society of
Hypertension meeting in Chicago, on behalf of
his colleagues involved in the ACCOMPLISH
clinical trial. The six-month data are published
simultaneously in the journal Blood Pressure.
The goal of the ACCOMPLISH
study, begun in 2003 and funded by Novartis, is
to compare the impact of two different two-drug
combinations on the long-term health of a global
sample of people with hypertension. Novartis
markets single-pill forms of both two-drug
products, but they are also available separately
as individual drugs.
The trial randomly assigned
patients to one of two drug combinations. Both
combinations contained a drug called benazepril,
which belongs to a class of medicines known as
ACE inhibitors. The other drug in one of the
combinations is a diuretic called
hydrochlorothiazide; in the other combination
pill, it’s a drug called amlodipine, one of a
class of medicines called calcium channel
blockers.
It is too early to say if
one of the combinations surpasses the other in
bringing blood pressure down or in preventing
cardiovascular problems and death.
But because many studies
have already shown that reducing blood pressure
can reduce the risk of stroke, heart attack,
heart failure and other conditions, achieving
blood pressure control in large percentages of
high-risk people is an accomplishment in itself,
says Jamerson.
Currently, blood pressure
treatment guidelines call for a single medicine
to be tried first in people with Stage 1
hypertension -- those with the top, or systolic,
reading over 140 and the bottom, or diastolic,
reading over 90, but with readings less than 160
systolic and 100 diastolic.
As many as 60 million
Americans have high blood pressure. But because
high BP doesn’t cause symptoms, most people who
have it don’t know it. Over time, uncontrolled
blood pressure affects the blood vessel walls,
encouraging the growth of weak spots called
aneurysms and the formation of narrowed and
inflamed areas that can lead to clots that can
break off and cause heart attacks and strokes.
Only 30 percent of
Americans who have high blood pressure, and only
60 percent of those taking medicines for
hypertension, currently have their blood
pressure under control.
Fortunately, once the
condition is diagnosed, doctors have a broad
range of medicines to choose from to try to get
it under control, including many inexpensive
generic medicines.
But studies have found that
patients often have trouble taking the multiple
medications they need. As a result, many
companies have developed combination pills. The
ACCOMPLISH data suggest these combination
tablets have the potential to improve control
rates to over 80 percent.
ACCOMPLISH stands for
Avoiding Cardiovascular Events through
Combination Therapy in Patients Living with
Systolic Hypertension.
In addition to Jamerson,
the study’s authors include Bertram Pitt and
Sverre Kjeldsen of the U-M Cardiovascular
Center; senior author Michael Weber of SUNY
Downstate Medical College; George Bakris of the
University of Chicago; Bjorn Dahlof of
Sahlgrenska University Hospital in Sweden; Eric
Velazquez of Duke University; Jitendra Gupte,
Martin Lefkowitz, Allen Hester and Victor Shi of
Novartis; William Cushman of the University of
Tennessee and Vasilios Papademetriou of
Georgetown University.